The demonstration that naked plasmid DNA can induce strong immune responses in mice has attracted considerable attention in the vaccine community. However, similar immunizations have been less/not effective in clinical trials during the past decade, and the underlying mechanisms remain unknown. In this study, we hypothesized that some DNA-binding proteins in human serum may serve as host barriers, responsible for the low efficiency of plasmids' transfection in vivo. Using proteomics, we showed that human serum amyloid P component (hSAP) is specifically present in human DNA-protein complexes. Further analysis indicated that hSAP effectively binds plasmid DNA, inhibits DNA transfection into somatic cells and facilitates the endocytosis of DNA by macrophages, whereas mouse SAP (mSAP) has similar, but much weaker, activities. In the presence of hSAP, the plasmid DNA expression in vivo and plasmid DNA-induced immune responses also significantly decreased. Therefore, our results suggest that hSAP contributes to extracellular DNA clearance and the inhibition of plasmid DNA transfection in vivo. This mechanism may be partly responsible for the insufficient immune responses to DNA vaccination in human beings; therefore, it may serve as a novel target for the improvement of DNA vaccines and DNA-based gene therapy.
INTRODUCTION
Naked plasmid DNA is a potential vaccine modality for immunization against infectious disease agents, such as HIV, malaria and emerging strains of influenza. [1] [2] [3] [4] However, despite its great success in mice, the use of DNA vaccines has been greatly limited by their failure to sufficiently elicit potent immune responses in large animals, especially in human beings, [5] [6] [7] and it has become an urgent problem in human DNA vaccine studies. Many previous studies have indicated that the limited immunogenicity of plasmid DNA in human beings is associated with the low antigen expression, resulting from insufficient transfection efficiency. 4, 8 Some reports have also shown that, in most cases, multiple high doses of DNA vaccine are always necessary to increase the transfection efficiency in human beings 6, 7 compared with the situations in mice. However, the molecular mechanism of DNA transfection in vivo, in particular, the potential agents serving as DNA barriers, remains undefined by far. Therefore, we investigated whether some species-specific inhibiting agents in the human body inhibit the efficacy of DNA vaccines.
Recent accumulating reports have indicated that free extracellular DNA is a potential risk because it has been recognized as an immunostimulatory factor that induces the production of type-I interferons (IFNs) and pro-inflammatory cytokines by fibroblasts or immune cells, which subsequently triggers inflammation [9] [10] [11] and autoimmune diseases. 12, 13 Thus, DNA clearance is essential for maintaining an internal homeostatic environment in human beings, especially after the intradermal or intramuscular injection of a large amount of plasmid DNA vaccine. Many molecules, such as serum amyloid P component (SAP), 14 C4b-binding protein, 15 mannosebinding lectin, 16 high-mobility group B proteins, 17 LL37 18 and heparan sulfate proteoglycan, 19 have been reported to have strong DNA-binding activity in the extracellular environment, especially in the serum. Some of these molecules may contribute to DNA clearance and, therefore, form barriers against the inflammation induced by exogenous DNA. 15 In this regard, we hypothesized that certain extracellular molecules may facilitate the clearance of extracellular DNA after plasmid inoculation and, subsequently, contribute to the low transfection efficiency of DNA vaccines in vivo, especially in the human beings.
To identify the molecules of interest, we hypothesized that the candidates should at least have three properties: (1) they should bind plasmid DNA (supercoiled or linear) under physiological conditions; (2) they should be present in the serum or in the extracellular matrix at the inoculation site, where they have the opportunity to bind exogenous DNA; and (3) they should have some DNA clearance activity. Therefore, we first identified and examined different DNAbinding proteins in human and mouse serum (Supplementary Figure S1 and Supplementary Tables S1-3), among which human SAP (hSAP) was the most intriguing candidate. First, it is well known that hSAP is the major genomic DNA-binding protein in human plasma, 14 although its plasmid-binding ability requires further validation; in contrast, mouse SAP (mSAP) only has a very weak DNA-binding activity. 20 Furthermore, hSAP is constitutively present in human serum at 20-40 mg ml À1 and is a normal component of basement membrane. 21 Most importantly, several reports have shown that SAP strongly binds to CD14 + monocytes 22 and opsonizes its ligands in an Fc receptor-dependent manner. [23] [24] [25] [26] In this regard, hSAP has been considered a candidate DNA vaccine 'scavenger' that requires further investigation. In this study, we investigated the plasmid-binding and the DNA clearance activities of hSAP and the role of SAP in plasmid transfection in vitro and in vivo.
RESULTS
hSAP is a species-specific plasmid-binding protein in human serum To test our hypothesis, we first examined the plasmid-binding ability of SAP, using a dot-blot immunoassays and a gel retention assay. We found that purified hSAP strongly bound both supercoiled plasmid and linear plasmid (Figures 1a and b) . Its physiological DNA-binding ability was confirmed using human serum or re-calcified plasma from healthy volunteers, and an SAP-specific, antibody-induced, dosedependent retention was also observed (Figure 1c) . On the contrary, neither the mSAP in mouse serum nor the purified mSAP showed significant DNA-binding ability, confirming the differential DNAbinding abilities of hSAP and mSAP. As a negative control, we used human C-reactive protein (hCRP), another plasma protein with various DNA-binding abilities, similar to SAP. We incubated the similar concentration of hCRP with the plasmid, but did not observe any complex formation (Figure 1b) .
To further determine the DNA-binding ability of hSAP, we used the gel retention assays in the presence of a variety of inhibitors. The hSAP-induced DNA retention was significantly inhibited by CHPHC (R-1-[6-[R-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl] pyrrolidine-2-carboxylic acid, an SAP-specific inhibitor that crosslinks and dimerizes SAP molecules) 27 (Figure 1d ). These results suggest that the natural pentamer structure is important for the binding of plasmid DNA by hSAP.
hSAP facilitates the plasmid DNA uptake and degradation by macrophages Previous studies have shown that hSAP can bind CD14 + monocytes and peripheral blood mononuclear cells (PBMCs) and opsonize its ligands for phagocytosis through Fc receptors. 25, 26 Therefore, we hypothesized that the hSAP in plasmid-protein complexes might facilitate the adsorption and phagocytosis of DNA when hSAP binds its membrane receptors on monocytes. To test this hypothesis, we first confirmed the monocyte-binding ability of the hSAP-DNA complex using the human promonocytic cell line THP-1-cell line-derived macrophages (MDMs) as a cell model. The DNA uptake efficiency was determined by flow cytometry, using the fluorescein isothiocyanate (FITC)-labeled plasmids. As a positive control, we used the well-known cell permeating peptides HIV-tat (TAT) 28 that can strongly bind DNA and facilitate DNA uptake. A time-dependent increase in the cellular association of naked plasmid DNA with MDMs was observed, and the fluorescence intensity significantly increased in the presence of hSAP compared with that in the presence of mSAP and hCRP (Figure 2a) . However, intracellular fluorescence-positive cells were rarely detected, even in the presence of hSAP or TAT (data not shown). We hypothesized that the naked DNA that was taken up was rapidly degraded by endosome nucleases; therefore, we used chloroquine (CL, a weak base that preferentially neutralizes acidic vesicles) to prevent DNA hydrolysis. In this way, we observed that the number of intracellular fluorescence-positive MDMs significantly increased in the presence of hSAP (Figure 2a ), indicating that hSAP facilitates the endocytosis of the plasmids into acidic endosomes and the subsequent degradation. Furthermore, the intracellular plasmid was significantly associated with the early endocytic vesicle marker transferring, as shown in the confocal analysis, suggesting that hSAPplasmid complex may be transported to the endosomes (Supplementary Figure S2 ).
It has been well known that the direct transfection of professional antigen-presenting cells has an important role in the immunogenicity of DNA vaccines. 29 We therefore explored whether hSAP facilitates the transfection and antigen expression of DNA vaccines in antigenpresenting cells, such as dendritic cells and macrophages. To this end, we investigated the expression of the plasmid in MDMs and PBMC-derived DCs (mDCs), in the presence of hSAP. Using luciferase reporter vectors and a jetPEI-macrophage transfection reagent as a positive control, we did not observe increased plasmid expressions in these cells (data not shown), indicating that the hSAP-plasmid complex does not facilitate the plasmid transfection or increase plasmid expression in antigen-presenting cells.
We then examined whether SAP-mediated endocytosis results in the plasmid clearance in vitro, thereby reducing the effective concentration of the DNA vaccine in vivo. We incubated 1Â10 4 THP-1 with increasing concentrations of plasmid in serum-free medium containing 40 mg ml À1 hSAP, mimicking the physiological hSAP concentration in human serum, and we quantified the plasmids remaining in the supernatants. The amount of the plasmids showed a significant and rapid decrease (Figure 2b ): 90% within 5 min. These results support the hypothesis that hSAP may facilitate plasmid DNA clearance, due to its monocyte-binding ability in vitro. hSAP inhibits plasmid transfection into non-phagocytic cells In most cases, intramuscular injection of the plasmid predominantly leads to the transfection of myocytes and the subsequent antigen expression. 4 Therefore, we investigated the potential effect of SAP on DNA uptake by non-phagocytic somatic cells. Recent studies indicate that several extracellular DNA-binding proteins, such as high-mobility group B 1, anti-microbial peptide LL37 and heparan sulfate proteoglycan, may be important for DNA uptake under physiological conditions. [17] [18] [19] 30 Therefore, we used two DNA-binding peptides, TAT and LL37, to simulate physiological transfection agents, as reported previously. Using the luciferase-expressing plasmid pGL4.17-CMV and two non-phagocytic cell lines, we found that the transfection efficiency of the plasmid significantly increased after a pre-incubation of LL37 or TAT. On the contrary, we did not observe such increase in the presence of hSAP (Figure 3a) . Interestingly, we also found that hSAP inhibited LL37-or TAT-mediated DNA transfection compared with control proteins, and that the inhibition was aborted by the CHPHC (Figure 3b ). Furthermore, we found that the efficiency of LL37-or TAT-mediated transfection decreased as much as 60% in the presence of human serum, and that CHPHC could also inhibit the transfection (Figure 3c ). These results suggest that hSAP cannot facilitate DNA uptake by non-phagocytic cells, but can inhibit peptide-mediated DNA transfection into those cells.
It is well known that both phagocytes and non-phagocytic cells are present at the inoculation site of DNA vaccines. Considering the DNA clearance ability of hSAP, we investigated whether phagocytes affect the plasmid transfection into non-phagocytic cells in the presence of hSAP. For in vitro analysis, we used a multiple cell culture system, supporting both the adherent non-phagocytic cells HEK293 and the suspension phagocytes THP-1, to study the competition for DNA uptake by multiple cells. The FITC-labeled plasmid pGL4. 17-CMV was added into the culture, using LL37 as a transfection agent. We found that DNA predominately entered HEK293 cells in the absence of hSAP, whereas the DNA uptake by THP-1 cells significantly increased in the presence of hSAP (Figure 3d ). The luciferase expression assays further showed that hSAP negatively affected the DNA transfection into HEK293 cells in the presence of THP-1 cells (Figure 3e ). These findings support our hypothesis that SAP facilitates DNA to enter macrophages and inhibits DNA transfection into nonphagocytic somatic cells, under physiological conditions. hSAP inhibits the plasmid expression in vivo in a mouse model To investigate the relationship between hSAP-mediated plasmid phagocytosis and vaccine antigen expression in vivo, an animal model is essential for further in vivo studies of hSAP. To this end, we first confirmed the strong ability of human SAP to bind murine macrophages and to facilitate plasmid DNA clearance in Raw264.7, a macrophage cell line initially derived from BALB/c mice. The results were very similar to those obtained from THP-1 (Supplementary Figure S3) , indicating that hSAP may have strong macrophagebinding ability and may contribute to DNA clearance in BALB/c mice. Therefore, BALB/c mice may be a proper model to investigate hSAP-mediated plasmid-macrophage interactions in vivo.
We used the plasmid pGL4.17-CMV as a model immunogen and an IVIS detection system 31 to investigate the functions of hSAP in mice. Using this system, we were able to readily measure the luciferase expression and to monitor its kinetics in living mice, following plasmid DNA immunization. To further investigate the effect of hSAP on DNA vaccination, three frequently used adjuvant strategies were utilized before DNA immunization: the pre-administration of lidocaine (LID), 32 the inoculation of a granulocyte-macrophage-colony-stimulating factor (GM-CSF)-producing plasmid (pCSF2) 33 and electroporation treatment. 34 As shown in the representative images (Figure 4a ) and by the mean values ( ± s.d.) (Figure 4b ), the vector expression levels in LID-pre-administrated mice and pCSF2-inoculated mice both significantly decreased after the pre-incubation of hSAP compared with those with the pre-incubation of hCRP at 24 and 72 h, whereas no significant luciferase expression difference was found between hSAP-and hCRP-incubated plasmids in electroporation-treated mice.
In our previous studies, we have shown that hSAP-mediated DNA clearance is associated with monocytes and macrophages. As LID-and GM-CSF-producing plasmids can induce both local inflammation and monocyte infiltration in muscles before DNA immunization, 32, 33 we further investigated the luciferase expression, following the two adjuvant inoculations in a long-time observation, and found that hSAP significantly inhibited plasmid expression in mice pre-treated with LID or pCSF2 compared with that in untreated mice (Figure 4c ), further supporting our hypothesis that hSAP can facilitate plasmid DNA clearance by macrophages in vivo.
hSAP attenuates the immunogenicity of the HBsAg DNA vaccine in vivo We next examined the role of hSAP in the humoral responses elicited by DNA vaccination. We used a hepatitis B surface antigen All samples were tested in duplicate. *Po0.05, **Po0.01 (two-tailed unpaired t-test, n¼3).
Human serum amyloid P inhibits DNA transfection in vivo Y Wang et al (HBsAg)-producing plasmid (pVAX-HBs) 35 as a model vaccine for inoculation into BALB/c mice. When mice were immunized with pVAX-HBs, their serum immunoglobulin G titers against the encoded HBsAg protein were significantly augmented; however, the titers in SAP-DNA immunized mice were significantly lower than those in the control (CHPHC-treated hSAP or mSAP) mice (Figure 5a ). The isotypes of HBsAg-specific immunoglobulin G showed similar changes (Figure 5b ). For cellular immunity, the secretion of IFN-g by splenocytes (Figure 5c ) and the frequency and cytotoxicity of antigen-specific CD8 + T cells (Figure 5d ) from mice immunized with the hSAP-plasmid complex were also significantly lower than those from the control mice. These results showed that hSAP-incubated pVAX-HBs elicited significantly weaker humoral and cellular immune responses than the untreated plasmids, suggesting that hSAP inhibits the immunogenicity of DNA vaccines in vivo. In terms of the SAP-specific inhibitor, CHPHC, we found that mice elicited comparable antigen-specific immune responses to the encoded antigen after CHPHC-hSAP-pVAX-HBs and pVAX-HBs vaccinations, indicating that CHPHC can abolish the inhibitory activity of hSAP during DNA immunization, therefore suggesting a further application of CHPHC in human DNA vaccine development.
DISCUSSION
A fundamental initial and determined step in DNA vaccination is that the DNA vaccine needs to be transfected into various types of cells in situ 36, 37 and then results in subsequent antigen expression in vivo. However, the transfection efficacy of DNA vaccine is significantly lower in human beings versus in mice. In this study, our results indicate that hSAP may be an important 'DNA scavenger' , which may avidly bind plasmid DNA, inhibit DNA transfection into somatic cells and facilitate the endocytosis of DNA by macrophages. Interestingly, the role of SAP in DNA clearance is very different in human beings versus mice. As reported in many studies, hSAP has a stable physiological concentration around 20-40 mg l À1 with an even higher C H P H C h C R P m S A P h S A P + C H P H C h S A P U N C H P H C h C R P m S A P h S A P + C H P H C h S A P U N C H P H C h C R P m S A P h S A P + C H P H C h S A P U N C H P H C h C R P m S A P h S A P + C H P H C h S A P U N DNA-binding affinity, 38 whereas mSAP is a major acute phase protein with widely differing concentration in different mouse strains. Although its value in all strains of mice rise greatly during the acute phase response, 39 the normal mice have a low concentration of SAP (around 5-10 mg l À1 in C57BL/6 mice and 40-60 mg l À1 in BALB/c mice), and their binding ability are much more weaker. 20, 38 We therefore suggest that human beings may have developed the highly effective regulation of SAP expression, and the subsequent capability to prevent invasion of exogenous DNA, during the evolution of the innate immune system. Unfortunately, hSAP may therefore be a barrier to effective DNA-based immunization and greatly limit the immunogenicity of DNA vaccines in the human beings.
Many studies have shown that SAP could opsonize apoptotic cells and zymosan through FcgRs, but on the contrary, SAP has been shown to be a potent anti-opsonin 40, 41 in some other reports. Specifically with respect to genomic DNA, SAP has been reported to protect chromatin against degradation. 42 In this study, we observed the engulfment of SAP-opsonized B-DNA by human MDMs and found that the SAP-DNA complex localized in the early endosome. We suggest that the different findings may be related to the length of DNA. The genomic DNA has a huge molecular weight and therefore uptake by macrophages is not possible before degradation. As hSAP potently protects chromatin against degradation, it may inhibit genomic DNA clearance in vivo. However, the plasmids with a small molecular weight could be phagocytosed after the opsonization of hSAP and may be gradually cleared by macrophages. The clearance of SAP-DNA complex may be helpful for maintaining the balance of DNA-related immunity during infection and tissue damage. In this study, we used mice as a model to investigate the functions of hSAP. In most cases, human proteins should induce antibody production after administration in mice, and their functions may be blocked in vivo. However, in our IVIS assays, hSAP was injected only once, and the follow-up observation lasted no more than 2 weeks. There was no anti-hSAP antibody production during this period. Meanwhile, we used hCRP as a negative control protein; hCRP has a very similar structure to hSAP. Both hCRP and hSAP have the Ca-dependent ligand-binding activity, but only hSAP has the DNAbinding ability. Therefore, hCRP may be a good control for the investigation of SAP.
In an attempt to identify a way to surmount the current barriers to effective DNA immunization, we also investigated the suppressive ability of hSAP in additional types of DNA vaccinations with different adjuvant strategies. As shown in our current studies, the presence of hSAP resulted in a significant decrease in expression level when LIDor GM-CSF-expressing plasmids were used as adjuvants for intramuscular DNA vaccination. These results suggest that local inflammation during intramuscular immunization may facilitate the clearance of plasmids and ultimately reduce the expression of DNA vaccines. Currently, both the pre-injection of local anesthetic (0.25% LID) to promote muscle regeneration and co-delivery of plasmid-encoded cytokines to recruit dendritic cells in situ have been widely reported to be efficient adjuvant strategies in mice-based DNA vaccine studies. However, both of the two strategies will induce local inflammation and monocytes infiltration in situ. We therefore suggested that the aggregated monocytes and macrophages may significantly clear the injected plasmid DNA in the presence of human SAP in human applications. In this regard, our results indicate that inflammationinducing adjuvants may inhibit DNA vaccines' efficacy in the presence of human SAP and should be re-evaluated in human applications.
In contrast, electroporation-adjuvant intramuscular DNA vaccination had a high efficacy both in the presence or absence of hSAP at physiological concentrations in our observation. We suggest that there are at least two reasons to explain it. Firstly, as electroporation does not induce significant monocyte infiltration in situ at the time of vaccination, the hSAP-mediated monocyte phagocytosis may be attenuated during this progress. Secondly, application of short electrical pulses to the target cells permeabilizes the cell membrane, thereby directly facilitating the DNA uptake into cytoplasm, 43 even in the presence of human SAP. We therefore suggest that electroporationadjuvant strategies may have better efficacy in increasing the expression level of DNA vaccines in human applications, which are consistent with the previous reported results. 44, 45 However, the electroporation can also induce cytokine secretion and inflammatory cell infiltration in the muscle hours after the treatment, 46, 47 which may also facilitate SAP-mediated clearance and limits the efficacy of DNA vaccines. We therefore suggest that electroporation should be preformed immediately after DNA inoculation.
On the basis of our findings, specific inhibitors of the DNA-binding activity of hSAP, for example, CHPHC, may also be a potential adjuvant for human DNA vaccines. The safety of SAP depletion by CHPHC administration has been recently confirmed in a clinical investigation. 48 We therefore suggest that SAP suppression by chemicals, such as CHPHC, might be a novel direction to enhance the efficiency of DNA immunization in human beings. We also suggest that some special nanomaterials that can prevent DNA vaccines from hSAP binding may be a potential novel adjuvant for human DNA vaccines. However, further investigations are still required to confirm these possibilities.
MATERIALS AND METHODS

Cell culture
HEK293 cells were cultured in DMEM (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Invitrogen). NIH3T3 and THP-1 cells were maintained in RPMI-1640 medium (Invitrogen) supplemented with 10% fetal bovine serum. To induce macrophage differentiation, phorbol-12-myristate-13-acetate (10 mg ml À1 ; Sigma-Aldrich, St Louis, MO, USA) was added into the THP-1 medium, and the cells were cultured for 3 days with daily medium replacement. Human immature mDCs were generated from blood monocytes obtained from PBMCs using anti-CD14 microbeads (Miltenyi Biotec, Auburn, CA, USA) and cultured for 5 days with GM-CSF and interleukin-4 (both from R&D Systems, Minneapolis, MN, USA).
Reagents, plasmids and sera preparation HIV-Tat peptide (GRKKRRQRRRPPQC-amide) and LL-37 peptide (LLGDFF RKSKEKIGKEFKRIVQRIKDFLRNLVPRTES) was synthesized by Sangon Biotech (Shanghai, China). hCRP, CL (both from Sigma-Aldrich), a goat polyclonal antibody both against hSAP and mSAP (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and jetPEI-macrophage transfection reagent (Polyplus Transfection, New York, NY, USA) were obtained from commodity. hSAP and mSAP was purified from human serum and mouse acute phase serum, respectively, as described earlier. 39, 49 A chemical SAP inhibitor DHPHC was synthesized according to previous reports. 27 Plasmid pGL4.17-CMV was constructed by inserting a DNA fragment containing a CMV promoter into the multiple cloning site of pGL4.17 (Promega, Madison, WI, USA). The DNA vaccine pVAX1-HBs was constructed as described previously. 35 Plasmid pCSF2 was constructed by inserting a cDNA fragment encoding mouse GM-CSF into pcDNA3.1 (Invitrogen). All plasmids were isolated using an Endo-free Plasmid Mega Kit (Qiagen China, Shanghai, China). In some cases, plasmid pGL4.17 was linearized using HindIII (Fermentas, Shenzhen City, China). For flow cytometry, pGL4.17 plasmids were labeled with FITC using Label-it Fluorescence Kit (Mirus Bio, Madison, WI, USA) as recommended by the manufacturer. Normal human serum and fresh PBMCs was obtained from healthy volunteers.
DNA-binding analyses
The binding of hSAP to DNA was evaluated using dot-blot and gel retardation analysis as described previously. 15 For dot blot, all blots were incubated with 5 mg ml À1 purified proteins or 10% serum diluted with TSC buffer (10 mM TrisHCl, 150 mM NaCl, 2 mM CaCl 2 , pH 8.0) for 15 min and visualized with an SAP-specific antibody. For gel retardation analysis, linear plasmids (0.2 mg) and proteins were mixed in TSC buffer and then separated on 1% agarose gel in 40 mM Tris-acetate buffer (without EDTA, pH 8.0). For the supershift experiments, 5% serum and 1 or 2 mg of the anti-SAP polyclonal antibody (Santa Cruz Biotechnology) was incubated with linear plasmids (0.2 mg).
DNA uptake in vitro
Uptake of fluorophore-labeled plasmid by cells was determined by flow cytometry as described. 30 For CL treatment, 100 mg ml À1 CL was administered in cell culture for 30 min and then removed by phosphate-buffered saline washing. For intracellular DNA analysis, cells were washed with phosphatebuffered saline containing dextran sulfate (100 mg ml À1 ) for three times to remove extracellular DNA. Peptides HIV-tat (20 mg ml À1 ) or hSAP (40 mg ml À1 ) was pre-incubated with FITC-labeled plasmids (8 mg ml À1 ) for 10 min in TSC buffer before being added into the culture. For multiple cell co-culturing studies, 1Â10 4 HEK293 cells and 1Â10 4 THP-1 cells was seeded in a 24-well plate. After an incubation of FITC-labeled plasmids in the presence hSAP or LL37 for 6 h, the THP-1 suspension cells were collected from the supernatant while the HEK293 adherent cells were collected by trypsinization. The cell-associated DNA in the two kinds of cells was then determined by flow cytometry, respectively.
DNA clearance in vitro
The quantitative analysis of plasmids clearance was performed as previously described with few modifications. 42 Plasmid pEGFP-N1 (Promega) (0.2 mg) in 10 ml TSC buffer were incubated at 37 1C with hSAP (4 mg) or hCRP (4 mg), and then were added into 100 ml 1640 medium containing 1Â10 4 THP-1 cells, respectively. HEK293 cells were also used as a negative control. After incubations as long as 3 h, the cells were spun down, DNA was extracted from the supernatant and plasmid pEGFP-N1 was quantified with quantitative real-time PCR. The primer pairs are as follows: TCGCTCTGCTAATCCTGTTAC (sense) and GCTCACGCTGTAGGTATCTC (antisense), and the annealing temperature is 58 1C.
In vivo bioluminescence measurement
The quantitative analysis of pGL4.17-CMV expression in vivo was performed using IVIS Lumina II (Caliper Life Sciences, Hopkinton, MA, USA) as described previously. 8, 38 The integration time was 1 min. Overlay images and luminescence measurements were made using the Living Image software (version 3.1; Caliper Life Sciences).
Animal immunization
Six-week-old female BALB/c mice were obtained from the Shanghai Laboratory Animal (Shanghai, China). The mice were maintained under specific pathogen free conditions, and the experimental protocols were approved by the SMMU Institutional Animal Care and Use Committee. For IVIS analysis, plasmid pGL4.17-CMV was pre-incubated with hSAP or hCRP in 50 ml TSC buffer for 10 min before inoculation into the quadriceps, and plasmids with TSC buffer were immunized as controls. Each group contained five mice and the experiments were repeated three times. As adjuvant strategies, LID (0.25% in 100 ml phosphate-buffered saline; Christian Medical, Shenyang, China) or plasmid pCSF2 (20 mg in 50 ml phosphate-buffered saline) was injected into the same quadriceps of mice 1 day before inoculation, or an electroporation treatment with ECM 830 Electroporator (BTX, Holliston, MA, USA) were performed 5 s after the incubation of plasmids. For DNA vaccine immunization, 50 mg pVAX-HBs were inoculated into the quadriceps every 2 weeks for three times. In some cases, 50 mg plasmids were pre-incubated with 30 mg hSAP, mSAP or hSAP and 10 mg CHPHC in 50 ml TSC buffer for 10 min before DNA vaccination.
Immunoassays
HBsAg-specific antibody analysis, spleen antigen-specific IFN-g production and antigen-specific CTL activity was performed as described previously. 35, 50 In brief, sera from the immunized mice were collected by tail bleeding 2 weeks after the last immunization for anti-HBsAg antibody ELISA assay. For the specific IFN-g assays, commercially available ELISA Kits (R&D Systems) were used according to their manuals. The stimulating peptide is the H-2 d -binding peptide IPQSLDSWWTSL (HBsAg S28-39). 51 
Statistical analysis
Differences between the groups were analyzed for statistical significance by the two-tailed unpaired Student's t-test, using the SPSS 11.5 (SPSS Inc., Chicago, IL, USA) software.
